Cohen Veterans Bioscience Expands Digital Health Platform with Early Signal Expertise

Early Signal subsidiary will expand CVB's role as a hub for translational research and data analytics to fast-track solutions for brain disorders.

Expanding its capabilities in digital health and data-driven research, Cohen Veterans Bioscience (CVB) today announced the formation of Early Signal, LLC, a wholly owned, non-profit subsidiary. The new subsidiary will be formed from the leadership and expertise of the Early Signal Foundation, which is winding down its operations, and allows CVB to continue its innovative approach to translational research to advance needed diagnostics and precision medicine for brain disorders.

Early Signal, LLC (EaSi), provides a leading digital health platform for recording and analyzing a range of information, reported from wearables and other sensors, directly related to the well-being of patients living with brain disorders. These behavioral, cognitive, physiological and contextual data can be used to quantify brain health, improving the ability of clinicians to diagnosis a wide range of brain disorders and to treat them using precision medicine approaches.

Digital health monitoring allows us to study brain health and disease in unprecedented ways,” said Magali Haas, MD, PhD, CEO and President of CVB. By tracking variables such as sleep, physical activity, stress and cognition, we may be able to better understand what changes over time and to develop earlier and preventive diagnostics and treatments to make a difference in patients’ lives.”

Early Signal’s unique focus on data analysis and development of disease-related algorithms can improve the care that patients receive every day by helping clinicians understand a patient’s unique presentation of disease and tailor their care accordingly.

In the clinical setting, passively and continuously captured data from wearable and home sensors can help clinicians better monitor their patient’s health and medical progress, opening the door for appropriate interventions. When it comes to certain rare diseases and underserved patient populations, this means that patients with previously under-studied conditions can now benefit from precision medicine that responds to their own individual needs,” said EaSi’s executive director, Daniela Brunner, PhD.

Cohen Veterans Bioscience is a growing hub for innovative approaches to diagnosing and treating brain disorders,” said Dr. Haas. Early Signal will fit into our portfolio of programs that leverage high-performance computing and data analytics to develop research-stage and clinical solutions for patients with brain disorders.”

Share this article:

More from CVB

Genome-wide association analyses identify 95 risk loci and provide insights into the neurobiology of post-traumatic stress disorder

New meta-analysis builds upon PTSD genetics research, providing a foundation for the development of precision therapies

Driving Progress: TBI Action Alliance Launches Multi-Pronged Initiative to Speed Development of Diagnostic and Therapeutic Solutions for Traumatic Brain Injury

About Cohen Veterans Bioscience (CVB)

Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.

For Media Inquiries

Please feel free to email us at